pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
DAIICHI SANKYO · news · pharmadog
← back to DAIICHI SANKYO
News mentioning DAIICHI SANKYO
46
stories
2d
Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
fiercebiotech
9d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
12d
BioSpace 2027 Best Places to Work shines light on most admired employers
biospace
20d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
24d
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
biospace
24d
8 companies hiring in New York
biospace
26d
GSK’s B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trial
fiercebiotech
27d
BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study
biopharma dive
27d
BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD cases
fiercebiotech
Oct 22, 26
ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says
biospace
Oct 2, 26
Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
endpoints
Sep 28, 26
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
Sep 28, 26
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
stat
Sep 28, 26
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharma dive
Sep 28, 26
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
biospace
Sep 28, 26
Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer
endpoints
Sep 28, 26
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
fiercebiotech
Sep 14, 26
Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
fiercebiotech
Sep 11, 26
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
Sep 11, 26
GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
fiercebiotech
Aug 28, 26
Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO
endpoints
Aug 28, 26
Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
fiercebiotech
Aug 27, 26
Chutes & Ladders—Vivace revs up C-suite ahead of pivotal push
fiercebiotech
Aug 26, 26
Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
biospace
Aug 10, 26
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win
endpoints
Aug 6, 26
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
Aug 3, 26
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
Jul 30, 26
Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
biospace
Jul 29, 26
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
Jul 28, 26
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
← prev
page 1 of 2
next →